Specifically, TWEAK’s role in multiple sclerosis (MS) has been delineated previously: its level in postmortem tissue is increased in MS patients [4], overexpression of TWEAK exacerbates the clinical symptoms of the experimental autoimmune encephalomyelitis (EAE), a murine MS model [5], and anti-TWEAK antibodies injections decrease the phenotype of the same EAE model [6]. Here, TNFSF12 is linked to multiple sclerosis.